TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8683652
Drug: Post-treatment instructions
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment instructions
Study: 31155298
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal treatment (CRCT)
Study: 26025328
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg choline/day
Study: 26025328
Drug: 930 mg
Normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 930 mg choline/day
Study: 15743150
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with external-beam radiation (EBRT)
Study: 15743150
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with brachytherapy
Study: 15743150
Drug: Whole-pelvic EBRT
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvic EBRT and hormonal therapy
Study: 15743150
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with brachytherapy without pelvic radiotherapy
Study: 1995258
Drug: Nifedipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (up to 20 mg)
Study: 6401229
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (TNG)
Study: 31889177
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (rods and implants with DEAE-Dextran and Quil-A)
Study: 31889177
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (rods and implants with either DEAE-Dextran or Quil A)
Study: 28190578
Drug: Quadpill (irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadpill (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, atenolol 12.5 mg)
Study: 25403919
Drug: AG-PUFA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-PUFA (3 g/day for 8 weeks)
Study: 25403919
Drug: EE-PUFA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE-PUFA (3 g/day for 8 weeks)
Study: 24954344
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine combined with intravenous patient-controlled analgesia (ITM-IVPCA)
Study: 22882288
Drug: Aggressive parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive parenteral nutrition (PN) (amino acids 3 g/kg per day and lipids 2 g/kg per day on first day of life)
Study: 22882288
Drug: Conventional PN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PN (amino acids 1.5 g/kg per day and lipids 1 g/kg per day on first day of life)
Study: 19543114
Drug: Concentrated formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated formula (CF) 87 kcal/100 mL for 8 weeks
Study: 19543114
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (SF) 67 kcal/100 mL for 8 weeks
Study: 12576934
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine 1,000 mg/m²/d plus leucovorin 30 mg/d on days 1 to 7 and 15 to 21 of each cycle (group A)
Study: 12576934
Drug: Intravenous 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5‐fluorouracil 400 mg/m²/d plus leucovorin 20 mg/m²/d on days 1‐5 of each cycle (group B)
Study: 10220204
Drug: 1600 i.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 i.u. daily oral alpha-tocopherol for 8 weeks
Study: 1340687
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms BIM (continuous s.c. infusion for 24 hours)
Study: 1340687
Drug: 1500 micrograms/24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 micrograms/24h BIM (as 500 micrograms x 3 s.c. injections, 750 micrograms x 2 s.c. injections, and continuous s.c. infusion)
Study: 1340687
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg IM of a long acting formulation of BIM
Study: 31279613
Drug: Telephone-administered psycho-education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered psycho-education with behavioral activation intervention (TBA)
Study: 18028017
Drug: Anastrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (5 years treatment)
Study: 9933696
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia (TEA) with 2% lidocaine (15-20 ml), midazolam (5-10 mg), and fentanyl (<250 microg)
Study: 2305976
Drug: CIT (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT (Conventional Intermittent 'Top-Up' Injections)
Study: 25747263
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a dose prescription of 35 Gy in five fractions
Study: 8853765
Drug: Mesalazine (Asacol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (Asacol 1.6 g daily)
Study: 8853765
Drug: Olsalazine (Dipentum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (Dipentum 1.0 g daily)
Study: 29195028
Drug: Mast cell
Normalized name: Mast cell protease 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mast cell stabilizer (1 mg ketotifen twice daily for three months)
Study: 29195028
Drug: Varicocelectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varicocelectomy followed by mast cell stabilizer (1 mg ketotifen twice daily for three months)
Study: 27067196
Drug: Dihydroartemisinin-piperaquine (DP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP), administered monthly from 6 to 24 months of age.
Study: 22305890
Drug: Atorvastatin in
Normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin in combination with carboplatin
Study: 22305890
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and carboplatin
Study: 20561549
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) use group
Study: 15778928
Drug: Basal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal glucose concentration (G (b)) assigned the value of fasting plasma glucose concentration (G (fast))
Study: 15778928
Drug: Basal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal glucose concentration (G (b)) assigned the value of plasma glucose concentration 180 minutes after the start of the IVGTT (G (180))
Study: 12835077
Drug: Novel drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drug delivery system with coarse dispersion (average particle size 1-150 microm)
Study: 11391543
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily for 3 years
Study: 2960494
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg twice daily
Study: 26865083
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% continuous wound infiltration (8 ml/h)
Study: 26865083
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received intraoperative low-dose ketamine, acetaminophen, NSAIDs, nefopam, and morphine PCA
Study: 26806502
Drug: Spironolactone (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25‐50 mg)
Study: 22985207
Drug: 1 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg·kg(‐1) intranasally (group N)
Study: 22985207
Drug: 1 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg·kg(‐1) buccally (group B)
Study: 17011500
Drug: MK-0557, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0557, 1 mg/day
Study: 8070826
Drug: Lidocaine prophylaxis
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine prophylaxis (1.5 mg/kg bolus followed by 2 mg/min infusion)
Study: 31647464
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (chemoprevention of KC)
Study: 29482983
Drug: Switch strategy
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch strategy (2 years of tamoxifen followed by 3 years of aromatase inhibitors)
Study: 29482983
Drug: Upfront treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront treatment (5 years of aromatase inhibitors)
Study: 29482983
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg per day for 5 years)
Study: 29482983
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg per day for 5 years)
Study: 29482983
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg per day for 5 years)
Study: 29482983
Drug: Upfront treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront treatment
Study: 24789736
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy for Primary Care (PST-PC)
Study: 20698956
Drug: Stroke volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume guided fluid therapy combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group)
Study: 20698956
Drug: Stroke volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume guided fluid therapy (SV group)
Study: 20698956
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous pressure guided fluid therapy (CVP group)
Study: 16055957
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/d) and calcium carbonate (500 mg/d)
Study: 16055957
Drug: Estradiol implant
Normalized name: Oestradiol Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol implant (25 mg, replaced every 6 mo)
Study: 16055957
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (500 mg/d) only (Control for alendronate group)
Study: 9973655
Drug: Ebselen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen (150 mg b.i.d. for 2 weeks)
Study: 550621
Drug: diisopropylamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: diisopropylamine (3 times 200 mg a day)
Study: 550621
Drug: reserpine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: reserpine (3 times 0.25 mg a day)
Study: 11991216
Drug: perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 4 mg once daily (n = 42)
Study: 11991216
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg once daily (n = 43)
Study: 9655533
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 10 mg/kg twice daily for 5 days
Study: 9655533
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 10 mg/kg twice daily for 10 days
Study: 8732151
Drug: Bushenhuoxue Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushenhuoxue Tablet (BSHX)
Study: 27797997
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication management (eMM) system implemented in paediatric wards, details on dosage and duration not specified.
Study: 27797997
Drug: Modified electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified electronic medication management (eMM) system implemented in the second paediatric hospital, details on dosage and duration not specified.
Study: 25428337
Drug: Adjunctive Buchang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Buchang Naoxintong Capsule (NXT)
Study: 25428337
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel 75 g)
Study: 20121658
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (22 or 44 mcg three times weekly)
Study: 20121658
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (44 mcg)
Study: 20121658
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (22 mcg)
Study: 17540662
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) implantation
Study: 12598816
Drug: Acetyl-L-carnitine (Alcar)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (Alcar)
Study: 1992304
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (rice-syrup solids)
Study: 1992304
Drug: Solution C
Normalized name: Salt solution combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution C (glucose-based solution, control)
Study: 6340973
Drug: Glucametacin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucametacin (420 mg daily for 20 days)
Study: 6340973
Drug: Ketoprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (300 mg daily for 20 days)
Study: 28060040
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cysticidal therapy mentioned)
Study: 23369024
Drug: Loxoprofen (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen (180 mg/day)
Study: 19587472
Drug: Ibuprofen 500
Normalized name: ibuprofen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 500 mg, three times a day for nine days
Study: 19587472
Drug: Mesalamine 400
Normalized name: mesalamine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 400 mg, three times a day for nine days
Study: 11772973
Drug: Terlipressin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (3 mg)
Study: 11772973
Drug: Albumin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (8 g/l of removed ascites)
Study: 9882082
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 12.5 mg
Study: 8071037
Drug: iopromide (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide (370 mg I/mL)
Study: 8071037
Drug: iohexol (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (350 mg I/mL)
Study: 241357
Drug: LF 17-895
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF 17-895 (10 mg oral dose)
Study: 241357
Drug: LF 17-895
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF 17-895 (4 mg intravenous dose)
Study: 241357
Drug: Pindolol (comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (comparison drug)
Study: 30575345
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group 2)
Study: 27626368
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (Group 1)
Study: 26044218
Drug: Nasotracheal suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasotracheal suction mechanical ventilation treatment (test group)
Study: 26044218
Drug: Noninvasive positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive positive pressure ventilation (CPAP) treatment (control group)
Study: 17187274
Drug: A +
Normalized name: Vital E- A + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A + HA group (arthroscopic knee joint lavage followed by 10 ml of 0.5% sodium hyaluronate)
Study: 15006059
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection of the prostate (TURP) plus sequential laparoscopic bladder diverticulectomy
Study: 11557928
Drug: Noncontact normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact normothermic wound therapy (3 treatments daily, dressing warmed to 38 degrees C for 1 hour)
Study: 11557928
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (moisture retentive dressings providing absorption as needed)
Study: 2091073
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Nitrendipine + Chlorthalidone)
Study: 31730174
Drug: Spironolactone-pioglitazone-metformin (SPIOMET)
Normalized name: metformin / pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone-pioglitazone-metformin (SPIOMET) for 1 year
Study: 31730174
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) for 1 year
Study: 24135894
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of avocado soybean unsaponifiables (ASU) for 3 months
Study: 10923219
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.15 IU/kg body weight)
Study: 10923219
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.15 IU/kg body weight)
Study: 10923219
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart and Human insulin
Study: 1343612
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with 30 mg of pentazocine and 5 mg of diazepam
Study: 1343612
Drug: Hematoma block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematoma block with 20 cc of 1.5% Xylocaine
Study: 30055335
Drug: Intensive prolonged
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive prolonged exposure therapy (exact details of dosage and duration not specified, but treatment is administered daily over a 3-week period)
Study: 2698946
Drug: Nifedipine AR
Normalized name: nifedipine Extended Release Oral Tablet [Adalat AR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine AR (20 mg twice a day)
Study: 2698946
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet twice a day)
Study: 31381231
Drug: Subcutaneous Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous Methotrexate (MTX)
Study: 28439994
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg once daily, adjustable to 100 or 25 mg as needed)
Study: 17275886
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 U, subcutaneous injections, once daily until ulcer healing or for a maximum of six months)
Study: 15457352
Drug: Talc slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc slurry (TS) 4 g
Study: 11037053
Drug: IL-2 presurgical
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 presurgical immunotherapy (12 million IU/day for 3 days subcutaneously)
Study: 11037053
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without IL-2 presurgical immunotherapy)
Study: 9272407
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch renewed on a new skin location
Study: 9272407
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch renewed on the previous application site
Study: 8386652
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: NCI regimen with vinblastine, etoposide, bleomycin and double dose cisplatin (PVeBV) 3 or 4 cycles Q3W
Study: 8386652
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: modified PVeBV protocol (bleomycin in continuous infusion) Q4W than a cycle of high-dose E + cyclophosphamide + P2 (PEC) and autologous bone marrow transplantation (ABMT)
Study: 20850847
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (100 pmol/L)
Study: 20850847
Drug: Medium-dose insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose insulin (400 pmol/L)
Study: 20850847
Drug: Hyperglycemia (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (12 mmol/L)
Study: 20850847
Drug: Lipopolysaccharide administration
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide administration (to mimic sepsis)
Study: 20850847
Drug: Euglycemia (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (5 mmol/L)
Study: 14592280
Drug: nCPAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP plus modafinil (200 mg/day for week 1; 400 mg/day for weeks 2-4)
Study: 23230283
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h for 7 days
Study: 23230283
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h (acute administration)
Study: 17028482
Drug: Amlodipine besylate/benazepril
Normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/benazepril HCl (5/20 mg/d force‐titrated to 5/40 mg/d)
Study: 17028482
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate monotherapy (5 mg/d force‐titrated to 10 mg/d)